123 related articles for article (PubMed ID: 36580432)
21. Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.
Hatta FH; Teh LK; Helldén A; Hellgren KE; Roh HK; Salleh MZ; Aklillu E; Bertilsson L
Eur J Clin Pharmacol; 2012 Jul; 68(7):1033-42. PubMed ID: 22294058
[TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
Wang B; Wang J; Huang SQ; Su HH; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):781-834. PubMed ID: 19925388
[TBL] [Abstract][Full Text] [Related]
23. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Hallberg P; Karlsson J; Kurland L; Lind L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
J Hypertens; 2002 Oct; 20(10):2089-93. PubMed ID: 12359989
[TBL] [Abstract][Full Text] [Related]
24. The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia.
Wu L; Fan Y; Wang Y; Li Z; Mao D; Zhuang W
J Clin Lab Anal; 2021 Oct; 35(10):e23949. PubMed ID: 34498315
[TBL] [Abstract][Full Text] [Related]
25. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
Wennerholm A; Nordmark A; Pihlsgård M; Mahindi M; Bertilsson L; Gustafsson LL
Eur J Clin Pharmacol; 2006 Jul; 62(7):539-46. PubMed ID: 16783563
[TBL] [Abstract][Full Text] [Related]
26. Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.
Dorado P; Machín E; de Andrés F; Naranjo ME; Peñas-Lledó EM; Llerena A;
Drug Metabol Drug Interact; 2012; 27(4):217-33. PubMed ID: 23093260
[TBL] [Abstract][Full Text] [Related]
27. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers.
Han Y; Guo D; Chen Y; Chen Y; Tan ZR; Zhou HH
Eur J Clin Pharmacol; 2009 Jun; 65(6):585-91. PubMed ID: 19221727
[TBL] [Abstract][Full Text] [Related]
28. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.
Yasar U; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
Eur J Clin Pharmacol; 2001 Dec; 57(10):729-35. PubMed ID: 11829203
[TBL] [Abstract][Full Text] [Related]
29. Structural and biophysical analysis of cytochrome P450 2C9*14 and *27 variants in complex with losartan.
Parikh SJ; Edara S; Deodhar S; Singh AK; Maekawa K; Zhang Q; Glass KC; Shah MB
J Inorg Biochem; 2024 Sep; 258():112622. PubMed ID: 38852293
[TBL] [Abstract][Full Text] [Related]
30. Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro.
Chen SZ; Pan PP; Shen LB; Xu SS; Dai DP; Geng PW; Cai J; Cai JP; Hu GX
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):732-8. PubMed ID: 24986093
[TBL] [Abstract][Full Text] [Related]
31. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.
Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA
J Clin Pharmacol; 2003 Jan; 43(1):84-91. PubMed ID: 12520632
[TBL] [Abstract][Full Text] [Related]
32. Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1).
Yasar U; Babaoglu MO; Bozkurt A
Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):176-9. PubMed ID: 18816302
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.
Gunes A; Coskun U; Boruban C; Gunel N; Babaoglu MO; Sencan O; Bozkurt A; Rane A; Hassan M; Zengil H; Yasar U
Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):197-200. PubMed ID: 16445595
[TBL] [Abstract][Full Text] [Related]
34. Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9.
Maekawa K; Adachi M; Matsuzawa Y; Zhang Q; Kuroki R; Saito Y; Shah MB
Biochemistry; 2017 Oct; 56(41):5476-5480. PubMed ID: 28972767
[TBL] [Abstract][Full Text] [Related]
35. The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes.
Mukai Y; Senda A; Toda T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):408-14. PubMed ID: 26551762
[TBL] [Abstract][Full Text] [Related]
36. [Development of the high resolution melting method for genotyping CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231)].
Cui GL; Ding H; Xu YJ; Chen C; Wang DW
Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Jun; 40(6):477-81. PubMed ID: 22943641
[TBL] [Abstract][Full Text] [Related]
37. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
Allabi AC; Gala JL; Horsmans Y
Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
[TBL] [Abstract][Full Text] [Related]
38. Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome.
Masajtis-Zagajewska A; Majer J; Nowicki M
J Renin Angiotensin Aldosterone Syst; 2021; 2021():2214978. PubMed ID: 34527078
[TBL] [Abstract][Full Text] [Related]
39. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.
Kang P; Cho CK; Jang CG; Lee SY; Lee YJ; Choi CI; Bae JW
Arch Pharm Res; 2023 May; 46(5):438-447. PubMed ID: 37097441
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Cabaleiro T; Román M; Ochoa D; Talegón M; Prieto-Pérez R; Wojnicz A; López-Rodríguez R; Novalbos J; Abad-Santos F
Drug Metab Dispos; 2013 Jan; 41(1):224-9. PubMed ID: 23118328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
